2024
Cohort study of patients with advanced cancer: outcomes associated with duration of antibiotic therapy for non-ventilator hospital-acquired pneumonia
Lee S, Benson J, Cohen A, Quagliarello V, Juthani-Mehta M, Datta R. Cohort study of patients with advanced cancer: outcomes associated with duration of antibiotic therapy for non-ventilator hospital-acquired pneumonia. Antimicrobial Stewardship & Healthcare Epidemiology 2024, 4: e48. PMID: 38655023, PMCID: PMC11036428, DOI: 10.1017/ash.2024.54.Peer-Reviewed Original ResearchNon-ventilator hospital-acquired pneumoniaAdvanced cancerPalliative care settingHospital-acquired pneumoniaCohort study of patientsCare settingsOlder adultsAdjusted oddsDuration of antibiotic therapyAssociated with reduced adjusted oddsSingle-center observational studyCohort studyProlonged antibiotic durationObservational studyStudy of patientsAntimicrobial stewardship effortsAntibiotic durationAntibiotic therapyStewardship effortsPneumoniaCancerOddsReadmissionAdultsCohort
2022
Prevalence and treatment of postobstructive pneumonia among older adults with advanced cancer
Lee S, O’Donovan L, Cohen A, Gautam S, Quagliarello V, Juthani-Mehta M, Datta R. Prevalence and treatment of postobstructive pneumonia among older adults with advanced cancer. Antimicrobial Stewardship & Healthcare Epidemiology 2022, 2: e152. PMID: 36483405, PMCID: PMC9726473, DOI: 10.1017/ash.2022.293.Peer-Reviewed Original ResearchClinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy
Tuan J, Kayani J, Fisher A, Kotansky B, Dembry L, Datta R. Clinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy. Antimicrobial Stewardship & Healthcare Epidemiology 2022, 2: e83. PMID: 36483361, PMCID: PMC9726471, DOI: 10.1017/ash.2022.229.Peer-Reviewed Original ResearchDalbavancin administrationOutpatient parenteral antimicrobial therapyDose of dalbavancinMedian antibiotic durationSoft tissue infectionsParenteral antimicrobial therapyAntibiotic durationDeveloped hepatotoxicityClinical cureSeptic arthritisClinical outcomesAntimicrobial therapyPatientsAdministrationDaysEndocarditisArthritisBacteremiaOsteomyelitisHepatotoxicityTherapyDalbavancinInfectionDose